151 related articles for article (PubMed ID: 21460782)
1. Thyroid function in Fabry disease before and after enzyme replacement therapy.
Faggiano A; Severino R; Ramundo V; Russo R; Vuolo L; Del Prete M; Marciello F; Lombardi G; Cianciaruso B; Colao A; Pisani A
Minerva Endocrinol; 2011 Mar; 36(1):1-5. PubMed ID: 21460782
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of subclinical hypothyroidism in patients with Anderson-Fabry disease.
Hauser AC; Gessl A; Lorenz M; Voigtländer T; Födinger M; Sunder-Plassmann G
J Inherit Metab Dis; 2005; 28(5):715-22. PubMed ID: 16151903
[TBL] [Abstract][Full Text] [Related]
3. Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents.
Wood LC; Ingbar SH
J Clin Invest; 1979 Nov; 64(5):1429-36. PubMed ID: 91625
[TBL] [Abstract][Full Text] [Related]
4. Biologic blood markers reflecting thyroid hormone effect at peripheral tissue level in patients receiving levothyroxine replacement for hypothyroidism.
Földes J; Tarján G; Bános C; Németh J; Varga F; Büki B
Acta Med Hung; 1991; 48(1-2):33-43. PubMed ID: 1813856
[TBL] [Abstract][Full Text] [Related]
5. Impaired action of thyroid hormone associated with smoking in women with hypothyroidism.
Müller B; Zulewski H; Huber P; Ratcliffe JG; Staub JJ
N Engl J Med; 1995 Oct; 333(15):964-9. PubMed ID: 7666915
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy and Fabry nephropathy.
Warnock DG; Daina E; Remuzzi G; West M
Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
[TBL] [Abstract][Full Text] [Related]
7. Biologic markers in blood reflecting thyroid hormone effect at peripheral tissue level in patients receiving levothyroxine replacement for hypothyroidism.
Földes J; Tarján G; Bános C; Németh J; Varga F; Büki B
Exp Clin Endocrinol; 1992; 99(3):129-33. PubMed ID: 1526260
[TBL] [Abstract][Full Text] [Related]
8. [Subclinical hypothyroidism].
Heureux M; Corvilain B
Rev Med Brux; 2004 Jun; 25(3):141-7. PubMed ID: 15291445
[TBL] [Abstract][Full Text] [Related]
9. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism.
Siegmund W; Spieker K; Weike AI; Giessmann T; Modess C; Dabers T; Kirsch G; Sänger E; Engel G; Hamm AO; Nauck M; Meng W
Clin Endocrinol (Oxf); 2004 Jun; 60(6):750-7. PubMed ID: 15163340
[TBL] [Abstract][Full Text] [Related]
10. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
[TBL] [Abstract][Full Text] [Related]
11. Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A.
Machann W; Breunig F; Weidemann F; Sandstede J; Hahn D; Köstler H; Neubauer S; Wanner C; Beer M
Eur J Heart Fail; 2011 Mar; 13(3):278-83. PubMed ID: 21149315
[TBL] [Abstract][Full Text] [Related]
12. Thyroid function in cord blood.
Henry G; Sobki SH; Al-Beshara NM; Harkonen ME; Miller HR
Saudi Med J; 2000 Jan; 21(1):36-9. PubMed ID: 11533748
[TBL] [Abstract][Full Text] [Related]
13. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
Breunig F; Wanner C
J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
[TBL] [Abstract][Full Text] [Related]
14. [Thyroid function in patients with Yusho].
Tsuji H; Ito Y
Fukuoka Igaku Zasshi; 2003 May; 94(5):103-7. PubMed ID: 12872709
[TBL] [Abstract][Full Text] [Related]
15. [Subclinical hypothyroidism].
Vána S; Földes J; Nĕmec J; Zamrazil V; Bednár J; Zimák J
Vnitr Lek; 1990 Jun; 36(6):566-72. PubMed ID: 2219763
[TBL] [Abstract][Full Text] [Related]
16. [Subclinical hyperthyroidism and hypothyroidism].
Gheri RG; Colli E; Mansani R; Brandi ML
Recenti Prog Med; 2000 Nov; 91(11):588-93. PubMed ID: 11125953
[TBL] [Abstract][Full Text] [Related]
17. Elevations of thyroid-stimulating hormone during acute nonthyroidal illness.
Wong ET; Bradley SG; Schultz AL
Arch Intern Med; 1981 Jun; 141(7):873-5. PubMed ID: 7235805
[TBL] [Abstract][Full Text] [Related]
18. [Discrepancy between clinical status and in vitro thyroid function tests].
Ríos EP; Dutrem MT; Ruíz E; González P; Valverde C; Maisterrena JA
Arch Invest Med (Mex); 1974; 5(1):17-22. PubMed ID: 4136340
[No Abstract] [Full Text] [Related]
19. Fabry disease: treatment and diagnosis.
Rozenfeld PA
IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
[TBL] [Abstract][Full Text] [Related]
20. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
